The regulation of circulating peptide hormones has been amenable to study for some four decades now, since the development of radioimmunoassay. The ability to measure these molecules sensitively and specifically revolutionised endocrinology by allowing elucidation of their role in physiology, as well as making possible the diagnosis of diseases of their under-and overexpression. It was later found, primarily by using in vitro systems, that the concentration of cellular receptors for these hormones was not fixed but was also subject to regulation. Experiments using binding of radiolabelled ligands to plasma membrane receptors demonstrated that receptor density in the cell membrane was sensitive to changes in the cellular environment as well as to altered pericellular concentrations of the ligand. Experiments of this kind led to the concept of interdependence between circulating levels of peptide hormones and cognate receptors.
The recent cloning of receptors for many of the well known peptide hormones has resulted in a further 'quantum leap' in endocrine research. In particular, receptors for peptide hormones such as parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP), calcitonin, secretin, glucagon, and vasoactive intestinal peptide have been shown to belong to a distinct class of the much larger family of seven membrane-spanning domain receptors (1) . In most cases the struggle to isolate cDNA clones encoding cell surface receptors was long and tedious. However, the rewards have been rich indeed. Possession of the cDNA sequence suddenly enabled entry to a previously locked storehouse of knowledge relating to the chemical nature of receptors, their localisation and mode of function, the regulation of their expression, and the detection of disease-producing mutants.
Importantly, at a time when whole animal physiology had become unfashionable, the cloned cDNA provided probes to determine receptor regulation in situ. The article by Kawane et al. in this issue (2) is a good example of the new generation of physiological studies that combine physiological approaches with molecular biology. The rationale for this particular study was that nutritional status regulates bone turnover secondarily to regulation of a number of circulating skeletal agonists. The question addressed was whether the changes observed in fasting might also influence tissue levels of the common receptor for PTH/PTHrP (PTHR). The study indeed showed that food deprivation resulted in increased steady state levels of PTHR mRNA in bone and kidney. The kinetics and magnitude of the increase were different between bone and kidney, suggesting different regulatory mechanisms in the two tissues. These changes were reversible and receptor mRNA levels returned to control values upon refeeding. The different PTHR mRNA levels were very probably reflected in increased cell surface receptor density, since fasting also increased PTH stimulation of the renal adenylate cyclase system. Interestingly, other work has shown decreased PTH-responsive adenylate cyclase in the face of increased PTHR mRNA levels, suggesting that regulation of PTH sensitivity can also occur at one or more points distal to receptor synthesis (3) .
Previous studies in cultured cells have shown that PTHR expression can be modulated by a number of factors. These include homologous regulation by the PTH and PTHrP ligands themselves, and heterologous regulation by transforming growth factor-b, tumour necrosis factor-a, retinoic acid, glucocorticoids, angiotensin II and calcitriol (reviewed in 4). In addition, several studies have shown that growth of cells on certain extracellular substrates can modulate PTHR expression; this may be due to cellular interaction with the matrix structural proteins per se, or with cytokines such as insulin-like growth factor sequestered in the matrix. Clearly, receptor expression in situ will be the product of the total concurrent cellular influences. Kawane et al. have conducted preliminary investigations into the factors that cause the increased PTHR mRNA levels in the fasted state. Several of the above regulatory agents have been excluded. Homologous regulation by PTH was unlikely, since serum PTH levels increased rather than decreased in the fasted state. However, since PTHrP is produced and acts locally, it may be that local tissue levels of this molecule exert an important influence on the receptor levels. Neither local levels of PTHrP in bone and kidney nor the effect upon them of fasting is known at present. Fasting also caused increased serum corticosterone levels, although exogenously increasing corticosterone to similar levels in fed animals did not affect PTHR levels. Another potential regulator, calcitriol, was not responsive to fasting. Fasting led to decreased serum calcium concentrations, which could directly or indirectly act to upregulate the PTHR. In terms of the best understood role of PTH and its receptor to conserve calcium, a mechanism to sensitise cells to PTH in times of calcium stress makes good sense. However, there can be no simple reciprocal relationship between the extracellular calcium concentration and PTHR levels. In hypocalcaemic uraemic rats, for example, renal PTHR is greatly down-regulated (5) (7); these are likely to be differentially responsive to regulatory influences. Whereas P2 is utilised in primary osteoblasts and osteoblast-like cells, P1 is the predominant promoter operative in the kidney. However, the true situation has recently been shown to be more complex, with cellspecific expression of promoters P1 and P2 in discrete cell types in the kidney (8) . The potential for selective regulation of the PTHR in different cells of the kidney would be consistent with the different functional roles of the receptor. PTH binding to receptors in the glomerulus and at several sites along the nephron, including the proximal and distal convoluted tubules and the thick ascending loop of Henle, activates adenylate cyclase. PTH inhibits phosphate and bicarbonate reabsorption in the proximal convoluted tubule, which is also the site of stimulation of production of 1a,25-dihydroxyvitamin D 3 by PTH. In contrast, PTH stimulates calcium reabsorption in the thick ascending limb and the distal convoluted tubule. Moreover, new evidence suggests that the renal vascular smooth muscle and endothelial cells strongly express the PTHR gene (8) . Thus, in the future, methods will need to be devised to study the effects of various influences on specific cell types in complex organs such as the kidney.
Naturally occurring and constitutively active mutations of the PTHR and gene deletion experiments have indicated the importance of controlled and appropriate expression of the PTHR. Between these two extremes, it is possible that disregulation of the PTHR may lead to pathology, and physiological experiments will now be important to investigate the normal receptor response to situations such as the stress of fasting. One possible consequence of changes in receptor levels might be altered intracellular signalling. The relationship between receptor density in the cell membrane and activation of intracellular calcium-mediated signalling has been shown for both the thyrotrophin-releasing hormone (9) and PTH receptors (10) . It is therefore possible that the relative receptor density in target cells could influence the range of cellular responses to ligand binding.
